263 related articles for article (PubMed ID: 26563422)
21. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
22. Proteomic identification of alpha-2-HS-glycoprotein as a plasma biomarker of hypopharyngeal squamous cell carcinoma.
Tian WD; Li JZ; Hu SW; Peng XW; Li G; Liu X; Chen HH; Xu X; Li XP
Int J Clin Exp Pathol; 2015; 8(8):9021-31. PubMed ID: 26464644
[TBL] [Abstract][Full Text] [Related]
23. Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer.
Rzechonek A; Kaminska A; Mamczur P; Drapiewski A; Budzynski W
Adv Exp Med Biol; 2017; 955():51-57. PubMed ID: 27683215
[TBL] [Abstract][Full Text] [Related]
24. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
25. An approach of selecting appropriate markers from the primary tumor to enable detection of circulating tumor cells in patients with non-small cell lung cancer.
Warawdekar UM; Sirajuddin MM; Pramesh CS; Mistry RC
J BUON; 2015; 20(3):782-90. PubMed ID: 26214631
[TBL] [Abstract][Full Text] [Related]
26. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method.
Zhao J; Fan YX; Yang Y; Liu DL; Wu K; Wen FB; Zhang CY; Zhu DY; Zhao S
Int J Clin Exp Pathol; 2015; 8(2):1535-44. PubMed ID: 25973038
[TBL] [Abstract][Full Text] [Related]
27. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
Shevchenko VE; Arnotskaya NE; Zaridze DG
Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
[TBL] [Abstract][Full Text] [Related]
28. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
[TBL] [Abstract][Full Text] [Related]
29. Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.
Hocker JR; Deb SJ; Li M; Lerner MR; Lightfoot SA; Quillet AA; Hanas RJ; Reinersman M; Thompson JL; Vu NT; Kupiec TC; Brackett DJ; Peyton MD; Dubinett SM; Burkhart HM; Postier RG; Hanas JS
Cancer Invest; 2017 Oct; 35(9):573-585. PubMed ID: 28949774
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
31. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
[TBL] [Abstract][Full Text] [Related]
32. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
33. Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.
Pietrowska M; Polańska J; Suwiński R; Wideł M; Rutkowski T; Marczyk M; Domińczyk I; Ponge L; Marczak L; Polański A; Widłak P
Int J Oncol; 2012 Jan; 40(1):148-56. PubMed ID: 21894432
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer.
Yang J; Yang F; Nie J; Zou X; Tian H; Qin Y; Liu C
Cancer Biomark; 2015; 15(2):205-11. PubMed ID: 25519022
[TBL] [Abstract][Full Text] [Related]
35. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
36. Proteomic profiling of serum from stage I lung squamous cell carcinoma patients.
Li XJ; Wu QF; He DL; Fu JK; Jin X
Asian Pac J Cancer Prev; 2013; 14(4):2273-6. PubMed ID: 23725126
[TBL] [Abstract][Full Text] [Related]
37. Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas.
Lapère C; Cortot AB; Grégoire V; Cockenpot V; Tulasne D; Copin MC
Am J Surg Pathol; 2017 Mar; 41(3):414-422. PubMed ID: 28098570
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis.
Bahar B; Acedil Ayc Iota B; Çoşkun U; Büyükberber S; Benekli M; Yildiz R
Asian Pac J Cancer Prev; 2010; 11(3):709-12. PubMed ID: 21039040
[TBL] [Abstract][Full Text] [Related]
39. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
40. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
